BiotechTube
STipe Therapeutics

STipe Therapeutics

Copenhagen, Denmark· Est.
stipetherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $26.5M

Overview

STipe Therapeutics is a private, preclinical-stage biotech founded in 2017 and based in Copenhagen, Denmark. The company is developing a proprietary platform of small molecule STING agonists engineered for targeted intratumoral delivery to reshape the tumor microenvironment and generate systemic anti-cancer immunity. Its lead program is advancing towards clinical trials, supported by venture capital funding and strategic research collaborations. STipe's approach aims to unlock the full potential of STING activation as a cornerstone of next-generation immuno-oncology combinations.

Oncology

Technology Platform

Proprietary platform for developing targeted small molecule agonists of the STING (Stimulator of Interferon Genes) pathway, designed for intratumoral injection to selectively activate immune cells within the tumor microenvironment.

Funding History

2
Total raised:$26.5M
Series A$21M
Seed$5.5M

Opportunities

The significant unmet need for effective immuno-oncology combination therapies to treat 'cold' tumors presents a major opportunity.
A successful, well-tolerated STING agonist could become a cornerstone combination partner with checkpoint inhibitors, addressing a multi-billion dollar market.
Demonstrating robust abscopal effects could further expand the utility to metastatic disease.

Risk Factors

High translational risk that promising preclinical data will not replicate in human trials.
Intense competition from multiple companies with STING programs, some already in clinical stages.
Operational and commercial challenges associated with an intratumoral injection therapy.
Dependence on raising additional capital to fund costly clinical development.

Competitive Landscape

The STING agonist field is highly competitive, with numerous biotech (e.g., Spring Bank Pharmaceuticals (now part of F-star), ImmuneSensor Therapeutics) and large pharmaceutical companies (e.g., Merck, Bristol Myers Squibb, GSK) developing candidates. Competition includes other small molecules, cyclic dinucleotides, and STING-targeting antibody-drug conjugates. Differentiation will hinge on therapeutic window, delivery, and clinical efficacy data.

More companies in Small Molecule Drugs →More companies in Denmark →